This HTML5 document contains 74 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB06811/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06811/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06811/identifier/national-drug-code-directory/
n20http://www.rxlist.com/
n18http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB06811/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n15http://linked.opendata.cz/resource/drugbank/drug/DB06811/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://www.drugs.com/international/
n9http://linked.opendata.cz/resource/atc/
n16http://www.pdrhealth.com/info/v1us/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06811
rdf:type
n3:Drug
n3:description
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena.
n3:dosage
n19:271B554C-363D-11E5-9242-09173F13E4C5 n19:271B554B-363D-11E5-9242-09173F13E4C5 n19:271B554A-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Peterson JD, Goldman MP, Weiss RA, Duffy DM, Fabi SG, Weiss MA, Guiha I: Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatol Surg. 2012 Aug;38(8):1322-30. doi: 10.1111/j.1524-4725.2012.02422.x. Epub 2012 May 23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22620717 # Weiss RA, Voigts R, Howell DJ: Absence of Concentration Congruity in Six Compounded Polidocanol Samples Obtained for Leg Sclerotherapy. Dermatol Surg. 2011 Mar 17. doi: 10.1111/j.1524-4725.2011.01906.x. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21414067 # http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_113.pdf # FDA label. # Lexicomp.
n3:group
approved
n3:halfLife
The half-life is approximately 1.5 h.
n3:indication
Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.
owl:sameAs
n18:DB06811
dcterms:title
Polidocanol
adms:identifier
n11:DB06811 n12:D01993 n13:46859 n14:46783-121-52 n15:Polidocanol
n3:mechanismOfAction
When administered, polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue.
n3:routeOfElimination
Route of elimination was not indicated.
n3:synonym
Lauryl monoethoxylate Ethylene glycol mono-N-dodecyl ether Hydroxyl polyethoxy dodecane Ethylene glycol monolauryl ether Lauromacrogol 2-Hydroxyethyl lauryl ether Laureth 9 Macrogol lauryl ether PEG-9 lauryl alcohol Polydocanol Oxypolyethoxydodecane Lauryl ethoxylate Dodecylpolyethyleneglycolether POE-9 lauryl alcohol
n3:toxicity
Most adverse reactions are related to the intravenous administration such as local irritation, pain, and hematoma. Extravasation can also be an issue.
n3:volumeOfDistribution
When given intravenously, the volume of distribution was 35-82L.
n3:proteinBinding
Plasma protein binding was not measured.
foaf:page
n7:asclera.html n16:asclera n20:asclera-drug.htm
n3:IUPAC-Name
n5:271B5551-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5557-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5556-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5553-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5554-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5555-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B554F-363D-11E5-9242-09173F13E4C5 n5:271B5567-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B554D-363D-11E5-9242-09173F13E4C5 n5:271B5550-363D-11E5-9242-09173F13E4C5 n5:271B556A-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B554E-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:C05BB02
n3:H-Bond-Acceptor-Count
n5:271B555D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B555E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5558-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5559-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B555B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B555A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B555C-363D-11E5-9242-09173F13E4C5
n3:absorption
When given intravenously, the maximum blood concentrations were reached in 15 mins.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
9002-92-0
n3:category
n3:clearance
Sytemic clearance was 0.2-0.4 L/min.
n3:Bioavailability
n5:271B5563-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n5:271B5569-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5565-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5566-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B5568-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B5562-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5561-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5564-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5552-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B555F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5560-363D-11E5-9242-09173F13E4C5